Первичная зрелая тератома яичка: клинические, морфологические и иммуногистохимические факторы прогноза

1. Mostofi F.K., Sesterhenn I.A. Pathology of germ cell tumors of testes. Prog Clin Biol Res 1985;203:1—34.

2. Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762—8.

3. Freedman L.S., Parkinson M.C., Jones W.G. et al. Histopathology in the prediction of of relapse of patients with stage I testicular treated by orchiectomy and alone. Lancet 1987;2:294—8.

4. Fung C.Y., Kalish L.A., Brodsky G.L. et al. Stage I nonsemimonatous germ cell tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 1988;6:1467—73.

5. Klepp O., Olsson A.M., Henrickson H. et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8:509—18.

6. Leibovitch I., Foster R.S., Ulbright T.M., Donohue J.P. Adult primary pure teratoma of the testis. Cancer 1995;75:2244—50.

7. Simmonds P.D., Lee A.H.S., Theaker J.M. et al. Primary pure teratoma of the testis. J Urol 1996;155:939—42.

8. Heidenreich A., Moul J.W., McLeod D.G. et al. The role of retroperitoneal lymphadenectomy in mature teratoma of the testis. J Urol 1997;157:160—3.

9. Rabbani F., Farivar-Mohseni H., Leon A. et al. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology 2003;62:1092—6.

10. Sesterhenn I.A., Weiss R.B., Mostofi F.K. et al. Prognosis and other clinical correlates of pathologic review in stage I and stage II testicular carcinoma: a report from the testicular cancer intergroup study. J Clin Oncol 1992;10:69—78.

11. Moul J.W., McCarthy W.F., Fernandez E.B., Sesterhenn I.A. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994;54(2):362—4.

12. Heidenreich A., Sesterhenn I.A., Mostofi K.F., Moul J.W. Prognostic risk factors to predict patients at low risk and at high risk for metastasis in clinical stage I nonseminomatous germ cell tumors. Cancer 1998;82:1002—11.

13. Sella A., El Naggar A., Ro J.Y. et al. Evidence of malignant features in hitsologically mature teratoma. J Urol 1991;146(4):1025—8.

14. Baniel J., Foster R.S., Gonin R. et al. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170—6.

15. Fung C.Y., Kalish L.A., Brodsky G.L. et al. Stage I nonseminomatous germ cell tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 1988;6:1467—73.

16. Andre F., Fizazi K., Culine S. et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000;36:1389—94.

17. Sturgeon J.F., Jewett M.A., Alison R.E. et al. Surveillance after orchiectomy for patients with clinical stage I nonseminomatous germ cell tumors. J Clin Oncol 1992;10:564—8.

18. Stevens M.J., Norman A.R., Fisher C. et al. Prognosis of testicular teratoma differentiated. Brit J Urol 1994;73:701—8.

19. Borge N., Fossa S.D., Ous S. et al. Late recurrence of testicular cancer. J Clin Oncol 1988;6:1248—54.

20. Nicolai N., Pizzocaro G. Ten year follow-up of a surveillance study in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1995;153(Suppl):245A:abstr #65.

21. Baniel J., Foster R.S., Rowland R.G. et al. Complications of primary retroperitoneal lymph node dissection. J Urol 1994;152:424—6.

22. Heidenreich A., Albers P., Hartmann M. et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003;169:1710—4.

23. Rabbani F., Gleave M.E., Coppin C.M. et al. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy: case for primary retroperitoneal node dissection in stage IIB germ cell tumors with teratomatous elements. Cancer 1996;78:480—6.

24. Beck S.D.W., Foster R.S., Bihrle R. et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in postchemotherapy nonseminomatous testis cancer. J Urol 2002;168:1402—4.

25. Heidenreich A., Seger M., Schrader A.J. et al. Surgical considerations in residual tumor resection following chemotherapy for advanced testicular cancer. Eur Urol 2004;(Suppl 3):161; abstr #632.

26. Albers P., Weissbach L., Krege S. et al. for the German Testicular Cancer Study Group. Prediction of Necrosis after chemotherapy of advanced germ cell tumors: results of prospective multicenter trial of German Testicular Cancer Study Group. J Urol 2004;171(5):1835—8.

27. Steyerberg E.W., Keizer H.J., Fossa S.D. et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177—87.

28. Oldenburg J., Alsen G.C., Lien H.H. et al. Postchemotherapy retroperitoneal surgery for nonseminomatous germ cell tumours: recommendations for patient selection. J Clin Oncol 2003;21:3310—5.

29. Patel M.I., Beck S., Bosl G. et al. Histology of good risk non-seminomatous germ cell tumor (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after four cycles of etoposide and cisplatin (Epx4). J Urol 2003;169(Suppl):176; abstr #681.

30. Fossa S.D., Qvist H., Stenwig A.E. et al. Is postchemotherapyretroperitoneal surgery necessary in patients with nonseminonatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569—74.